Research analysts at HC Wainwright started coverage on shares of Mersana Therapeutics (NASDAQ:MRSN) in a research report issued to clients and investors on Thursday. The brokerage set a “buy” rating on the stock.
Several other brokerages have also recently issued reports on MRSN. Zacks Investment Research cut shares of Mersana Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. ValuEngine upgraded shares of Mersana Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.67.
Shares of Mersana Therapeutics (NASDAQ:MRSN) opened at $15.36 on Thursday. Mersana Therapeutics has a fifty-two week low of $12.45 and a fifty-two week high of $21.01.
A number of hedge funds have recently modified their holdings of MRSN. Vanguard Group Inc. purchased a new stake in Mersana Therapeutics in the second quarter worth approximately $1,048,000. FMR LLC purchased a new stake in Mersana Therapeutics in the second quarter worth approximately $23,926,000. Goldman Sachs Group Inc. purchased a new stake in Mersana Therapeutics in the second quarter worth approximately $699,000. Bank of New York Mellon Corp purchased a new stake in Mersana Therapeutics in the third quarter worth approximately $231,000. Finally, California State Teachers Retirement System bought a new position in Mersana Therapeutics in the third quarter worth approximately $142,000. Institutional investors own 76.71% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Initiates Coverage on Mersana Therapeutics (MRSN)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another website, it was illegally copied and republished in violation of international copyright and trademark laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/17/hc-wainwright-initiates-coverage-on-mersana-therapeutics-mrsn.html.
About Mersana Therapeutics
Mersana Therapeutics, Inc is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug’s chances of attacking cancers.
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.